Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents

References

• Monte MJ, Marin J, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15(7):804–816.
   PubMed Web of Science ®Google Scholar
• Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15(14):1677–1689.
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis. 2013;17(2):161–189.
   PubMed Web of Science ®Google Scholar
• Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50:1509–1520.
   PubMed Web of Science ®Google Scholar
• Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis. 2010;28:220–224.
   PubMed Web of Science ®Google Scholar
• Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed. 2009;5(2): 1–9.
   Web of Science ®Google Scholar
• Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. J Gastroenterol Hepatol. 1998;13(6):659–664.
   PubMed Web of Science ®Google Scholar
• Heathcote EJ. Evidence-based therapy of primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 1999;11:607–615.
   PubMed Web of Science ®Google Scholar
• Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551.
   PubMedGoogle Scholar
• Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2010;4:473–488.
   PubMed Web of Science ®Google Scholar
• Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13:529–536.
   PubMed Web of Science ®Google Scholar
• Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med. 2000;108:481–486.
   PubMed Web of Science ®Google Scholar
• Carey EJ, Lindor KD. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol. 2012;36(1):S61–S64.
   Google Scholar
• Serfaty L, Bissonnette M, Poupon R. Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol Clin Biol. 2010;34(10):516–522.
   PubMed Web of Science ®Google Scholar
• Serfaty L. Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol. 2012;36(1):S53–S60.
   Google Scholar
• Komori Y, Arisawa S, Takai M, Yokoyama K, Honda M, Hayashi K, Ishigami M, Katano Y, Goto H, Ueyama J, Ishikawa T, Wakusawa S. Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells. Eur J Pharmacol. 2014;724:161–167.
   PubMed Web of Science ®Google Scholar
• Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(8):1631–1638.
   PubMed Web of Science ®Google Scholar
• Alexandrova RI, Kalfin RE, Leventieva-Necheva EV, Jivkova TD, Dyakova LV. Effect of ursodeoxycholic and deoxycholic acids on viability and proliferation of virus-transformed tumor cells. Compt Rend Acad Bulge Sci. 2010;63(12):1837–1844.
   Google Scholar
• Dyakova L, Culita DC, Marinescu G, Patron L, Kalfin R, Alexandrova R. The challenge of the brain tumors – searching for new therapeutic opportunities. Acta Morphol Anthropol. 2012;19:38–41.
   Google Scholar
• Dyakova, L, Leventieva-Necheva E, Zhivkova T, Marinescu G, Culita D, Patron L, Kalfin R, Alexandrova R. Effect of ursodeoxycholic acid on viability and proliferation of human tumor cells. Trakia J Sci. 2010;5(2):78–83.
   Google Scholar
• Culita DC, Marinescu G, Patron L, Ţuna F, Stanica N, Yun M. Coordination compounds of Co(II), Ni(II), Cu(II) and Zn(II) with ursodeoxycholic acid. Rev Roum Chim. 2010;55(1):63–67.
   Web of Science ®Google Scholar
• Alexandrov I. Immunobiological characterization of transplantable sarcoma in rats. Compt Rend Acad Bulg Sci. 1993;46:97–99.
   Google Scholar
• Alexandrova RI. Establishment, characterization and application of permanent cell lines from transplantable chicken hepatoma induced by the myelocytomatosis virus Mc29 [ dissertation]. Sofia: Bulgarian Academy of Sciences; 2009.
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett. 1985;24(2–3):119–124.
   PubMed Web of Science ®Google Scholar
• Saotome K, Morita H, Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol In Vitro. 1989;3(4):317–321.
   PubMed Web of Science ®Google Scholar
• Wahab SIA, Abdul AB, Alzubairi AS, Elhassan MM, Mohan SJ. In vitro ultramorphological assessment of apoptosis by Zerumbone on (HeLa). J Biomed Biotechnol. 2009;2009:46–55.
   Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35.
   PubMed Web of Science ®Google Scholar
• Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6(10):587–595.
   PubMed Web of Science ®Google Scholar
• Alexandrova R. Tumour heterogeneity. Exp Pathol Parasitol. 2001;4(6):57–67.
   Google Scholar
• Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N. From tumor cell metabolism to immune escape. Int J Biochem Cell Biol. 2013;45(1):106–113.
   PubMed Web of Science ®Google Scholar
• Achilli TM, Meyer J, Morgan JR. Advances in the formation, use and understanding of multi-cellular spheroids. Expert Opin Biol Ther. 2012;12(10):1347–1360.
   PubMed Web of Science ®Google Scholar
• Godugu C, Patel AR, Desai U, Andey T, Sams A, Singh M. AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One. 2013;8(1): e53708.
   PubMed Web of Science ®Google Scholar
• Corpechot C. Primary biliary cirrhosis and bile acids. Clin Res Hepatol Gastroenterol. 2012;36(1):S13–S20.
   Google Scholar
• Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol. 2012;36(1):S3–S12.
   Google Scholar